Literature DB >> 12054908

How blind is double-blind? A study of fish oil versus placebo.

Karen E Damico1, Andrew L Stoll, Lauren B Marangell, Bruce M Cohen.   

Abstract

The distinctive aftertaste associated with fish oil preparations used in clinical trials of omega-3 fatty acids may weaken the double-blind. This double-blind pilot study was designed to examine whether normal subjects could correctly 'guess' if they were receiving capsules containing concentrated fish oil or capsules of pure olive oil. The informed consent was designed to give subjects ambiguous expectations about what oil they might be receiving to examine whether this would influence their guess. Despite a marked difference in taste experience, there was no significant difference in correct guesses between the two groups. The results suggest that altering subjects' expectations could further improve the validity of the double-blind. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054908     DOI: 10.1054/plef.2002.0364

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  3 in total

1.  The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.

Authors:  Olivia I Okereke; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; Trisha Copeland; Georgina Friedenberg; Julie E Buring; JoAnn E Manson
Journal:  Contemp Clin Trials       Date:  2018-03-08       Impact factor: 2.226

Review 2.  Omega-3 fatty acids in the treatment of psychiatric disorders.

Authors:  Malcolm Peet; Caroline Stokes
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto.

Authors:  Jeannette Y Lee; Page Moore; John Kusek; Michael Barry
Journal:  J Altern Complement Med       Date:  2013-02-05       Impact factor: 2.579

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.